Corporaci3n Amrica Airports S. A. (NYSE: CAAP), the largest airport operator in the personal sector founded on the number of airports under management, announced that it will publish its quarterly effects so far on Thursday, August 20, following the close of markets.
About Corporaci3n Amrica Airports
Corporaci3n Amrica Airports acquires, develops and operates airport concessions. Currently, the Company operates 52 airports in 7 Latin American and European countries (Argentina, Brazil, Uruguay, Peru, Ecuador, Armenia and Italy). Passengers. The Company is indexed on the New York Stock Exchange, where it is listed under the symbol CAAP. For more information, http://investors. corporacionamericaairports. com.
BoaVida named fastest growing company through Sacramento Business Journal
AM Best withdraws ratings from Canassurance Hospital Service Association and its subsidiary
SINGAPORE, September 25, 2020 / PRNewswire / – A total of 81 projects and business leaders from across Asia have been chosen as beneficiaries of the Asia Responsible Enterprise Awards 2020 (AREA), an increase of 27% over last year. the benchmark for SRSE and sustainable development, this year’s awards rite was organized almost due to the unprecedented global fitness care crisis. A variety of leading industries and organizations across the region have won the IDM, demonstrating an ongoing commitment to guilty business practices despite the pandemic.
Organized through Enterprise Asia, Asia’s leading non-governmental organization for guilty entrepreneurship, IDN aims to recognize and honor Asian corporations and leaders for selling sustainable and socially guilty business practices. , corporate governance, leadership in circular economy and guilty corporate leadership. Through the award ceremony, this exclusive opportunity allowed more than six hundred participants to join and celebrate virtually.
According to Richard Tsang, newly elected president of Enterprise Asia, the pandemic has forced us to reconsider our values and balance the economic, social and environmental progress envisaged through the 2030 Agenda with the United Nations Sustainable Development Goals (UNSDG) in a moment. of the crisis, it is vital for us to make recovery a genuine opportunity to get things right in the future. “
Tsang added: “To date, the Asia Responsible Company Awards have shown more than six hundred successful Corporate Social Responsibility (RSE) projects, with millions of communities raised and billions of lives affected and saved. In the number of lives affected and saved, communities lifted, tears of joy shed, and how the long history of our young people and their young people is assured. There is no greater popularity to help make the world a bigger position than the satisfaction of witnessing the difference that has been made. “
This year, more than two hundred presentations were won from 19 countries of organizations across Asia. Area judges, led by Dr. Eugen Chien, former Minister of the Environment of the Republic of Taipei, assessed the presentation during a three-month evaluation period.
According to Dr. Chien, “The jury was inspired by the quality and diversity of this year’s presentations and had the difficult task of comparing and determining this year’s finalists. Winners are determined not only through their efforts and results, but also through criteria such as effective delineation, network connection, wish identification, ability to measure, effective implementation, ability to succeed in target audiences, impact, leadership participation, institutionalization and continuity. “
Dr Chien added: “I am pleased that many participants this year have made greater efforts to manage the continuation of their SRSE projects. This leads to more sustainable projects that are more applicable to the target network and that create a greater impact than ever before. before this time of crisis. “
Notable winning assignments include NIPSEA Management Company Pte’s “Colorful Dream”. Ltd: Commonly known as Nippon Paint, the initiative was conceptualized as Nippon Paint’s RSE program, which focuses on the schooling and empowerment of youth and communities in Asia; The assignment “Strong and Transparent Corporate Governance Mechanism” through E. SUN Financial Holding Co. , Ltd. aims at corporate governance, the company has a well-designed directory choice system, which is a fair and open procedure for performing certain facets of board control, stakeholder interests, transparency and disclosure; ‘Rak Pan Sook: A circular solution to Bangchak Corporation Plc’s plastic waste problem’ is a public awareness and sustainability task that supports recycling of used polyethylene terephthalate (PET) bottles and lubricant boxes and transforms into usable products.
The region’s top coveted CSR occasion: AREA 2020 is edited through the official two-way PR spouse, Organizations: Circular Economy Club, CSRone Taiwan, Global Reporting Initiative (GRI), Malaysian Ministry of Science, Technology and Innovation, National Institute of Entrepreneurship and Innovation (NIEL) Cambodia, Institute of Global Environmental Strategies (IGES) Japan, Taiwan Institute for Sustainable Energy and Sustainable Development in Vietnam.
List of recipients of the Asia Responsible Enterprise Awards 2020
Media contact
Ms. Nerissa NgEnterprise Asia (60) 780 012 [email protected]
About Enterprise Asia
Enterprise Asia is a non-governmental organization that seeks to create an Asia rich in entrepreneurship as an engine of sustainable and progressive economic and social progress in a world of economic equality. Its two pillars of lifestyles are investment in other people and guilty entrepreneurship. Asia works with governments, NGOs and other organizations to publicize the competitiveness and progression of entrepreneurship, the economic prestige of others in Asia and ensure a legacy of hope, innovation and courage for the next generation. . org / for more information.
About Asia Responsible Enterprise Awards (AREA)
The Asia Responsible Enterprise Awards recognize and honor Asian corporations for defending sustainable and guilty entrepreneurship in the categories of green leadership, investment from others, fitness promotion, social empowerment, corporate governance, leadership in circular economy, and guilty corporate leadership. https://enterpriseasia. org/area/.
Related links:
https://www. enterpriseasia. org/
Clover Biopharmaceuticals, a global clinical biotechnology company aimed at the discovery and progression of vaccines and transformative biological treatments, announced positive preclinical knowledge showing that its protein-based COVID-19 S-Trimer vaccine candidate in mixture with GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) adjuvants induces a strong immune reaction and opposite coverage of SARS-CoV-2 in animal models. The manuscript describing the effects titled S-Trimer, a vaccine candidate for the COVID-19 subunit, induces protective immunity in non-human primates has been sent for peer review and can be viewed on an online prepress server in bioRxiv.
Joshua Liang, CEO of Clover Biopharmaceuticals, said: We are excited to share those vital preclinical effects that seem to indicate that our S-Trimer COVID-19 vaccine candidate vaccine induces immune coverage opposite SARS-CoV-2, and we are also satisfied with progress. and initial knowledge of our Phase 1 clinical trial comparing S-Trimer. More than ever, we remain committed to developing a safe, effective and available COVID-19 vaccine on a scale that can help the global pandemic.
Thomas Breuer, medical director of GSK Vaccines, commented: We are satisfied with the preclinical effects that, in combination with initial data from Phase 1 clinical data, underscore expectations that GSK’s pandemic adjuvant formula combined with clover antigen leads to a strengthening of the immune reaction with the promise of greater efficacy and dose-saving capabilities. Adjuvants are resilient teams in global combat that opposes the COVID-19 pandemic, and we look to the future to see the progress of GSK’s adjuvant pandemic vaccine.
Rob Janssen, Medical Director of Dynavax, commented: We are satisfied with the strong preclinical effects observed when the adjuvant CpG 1018 complex plus Alum of Dynavaxs was combined with the Clovers S-Trimer antigen. We are especially motivated by the absence of measurable viral load. in lung tissues, as well as in other clinical measures in non-human primates with SARS-CoV-2, and by reacting to Th1 polarized T cells in rodents. This knowledge demonstrates the possibility of CpG 1018 increasing effectiveness by controlling infection. We are proud to work with Clover on the progression of this COVID-19 vaccine and are committed to helping Clover manufacture the vaccine that will be available worldwide.
Dr. Peng Liang, founder and president of Clover and inventor of the Trimer-Tag generation, added, with an attached manuscript titled ‘Cryo-EM Design of S-Trimer, a vaccine candidate subunit for COVID-19 showing that our S-Trimer resembles the local SARS-CoV-2 antigen complex in atomic resolution, our comprehensive preclinical studies validate Trimer-Tag as a prospective platform generation for the progression of sub-Asian vaccines as opposed to existing and long-term wrapped RNA viruses.
The Clovers COVID-19 S-Trimer vaccine was developed by combining the complex triteric protein SARS-CoV-2 (S) with the patented Trimer-Tag technology. In preclinical studies, Adjuvant S-Trimer induced strong humoral immune responses mediated by Th1 cells in mice, rats and monkeys, with neutralizing antibody grades equivalent to or greater than the degrees observed in human serums. Convalescence. Rhesus macaques that won the vaccine and were subsequently exposed to SARS-CoV-2 virus opposed infection, as demonstrated through clinical observations (coverage opposed to body weight loss and higher temperature framework) and significant relief from viral load of lung tissue and swabs. Matrix without symptoms of improvement of the disease. Strong immune responses and coverage were observed when S-Trimer was administered with the GSK pandemic adjuvant system or dynavaxs CpG 1018 more alum. This positive preclinical knowledge supported the resolution to advance applicants for vaccines with adjuvants who use adjuvants in the ongoing Phase 1 clinical examination of S-Trimer Clovers in healthy adult and elderly participants.
In June 2020, Clover announced the initiation of a Phase 1 clinical trial, which is a randomized, non-observer, placebo-controlled trial to evaluate the type, reactogenicity and immunogenicity of coVID-19 S-Trimer multidose adjuvant. The exam completed the recruitment of 150 adult and elderly participants. Preliminary effects show that the vaccine is more likely and well tolerated, with maximum levels of neutralizing antibodies observed. Based on these initial effects, two hundred more participants will be recruited in an expansion of the Phase 1 dose, examined at the adjuvant and determined dose point of S-Trimer with the GSK pandemic adjuvant or the most alumious Dynavaxs CpG 1018 adjuvant complex. Vaccine until the end of 2020. Detailed Knowledge of Phase 1 will be made available in a peer-reviewed publication in the near future. Clinical trials and the Clovers COVID-19 vaccine This program is supported by investment and collaboration with the Coalition for Innovations in Epidemic Preparedness (CEPI).
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global clinical stage biogeneration company based on research that aims at the discovery, progression and commercialization of transformative biological therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. It has raised more than $200 million in total,capital since 2016, Clover is using its patented Trimer-Tag generation platform to expand new biological products targeting trimerization-dependent pathways. In addition, Clover leverages its internal GMP bioproduction functions for the large-scale production of its biological therapies. make a stop on our website: www. cloverbiopharma. com.
About the COVID-19 S-Trimer vaccine
Using Clovers’ patented Trimer-Tag technology, the S-Trimer is a subunit vaccine candidate for the SARS-CoV-2 protein subunit (S) trimming complex. , SARS-CoV-2 is also an RNA virus that has a high-tech triteric protein (S) in its viral envelope. The SarS-CoV-2 S-trimer protein is guilty of binding to the surface receptor of the host’s ACE2 cell phone and next viral entry, making it the number one target antigen for vaccine development. S-Trimer resembles the protein of the local triteric viral complex and an immediate expression formula based on a culture of mammalian mobiles is produced.
About Trimer-Tag Technology
Trimer-Tag is a state-of-the-art drug progression platform that allows the production of new fusion proteins that are covalently trimmed. Many primary disease targets feature triflation, such as the superfamily of tumor necrosis (TNF) things (involved in extrinsic apoptosis, co-stimulation and inflammation), as well as viral RNA antigens convicted of entering host cells. Clover uses its Trimer-Tag generation with a global IP position to expand recombinant trim melting proteins that can aim well at those on past indruggable routes.
For many years, reinsurance markets in sub-Saharan Africa, while small by global standards, have provided global reinsurers with an opportunity for diversification and successful profit growth. slow deterioration in the functionality of market participants, reducing the region’s access to potential new entrants.
In a new report on Best’s market segment, “Difficult operational situations provide demanding situations for sub-Saharan reinsurance markets,” AM Best notes that operating environments in sub-Saharan Africa remain a challenge for domestic and foreign companies, at most recently exacerbated by COVID. 19 pandemics, albeit of different gravity. Many regional markets face double-digit inflation and a depreciation of the local currency; For some countries, government instability and corruption have contributed to social unrest and political uncertainty. Despite these demanding situations, there are still prospects for expansion for the safe (re) sectors due to the region’s herbal resources, a young and developing population, and the slow progression of regulatory regimes.
The report also notes that regional capacity is limited. The capital base of sub-Saharan African reinsurers is sometimes too small to fully satisfy the desires of local markets number one, where the dangers of structure and power require significant capacity. the know-how needed to manage complex hazards and provide greater capacity than local market players. With some notable exceptions, local and regional reinsurers act as followers, in accordance with the terms and situations established through the leading reinsurer.
For a loose copy of this special report, visit http://www3. ambest. com/bestweek/purchase. asp?record_code=301471.
AM Best is a global credit rating agency, news editor and knowledge analytics provider specializing in the insurance industry. Headquartered in the United States, the company operates in more than a hundred countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, www. ambest. com.
SINGAPORE, Sept. 25, 2020 / PRNewswire / – A total of 81 projects and business leaders from Asia have been decided as winners.
For many years, reinsurance markets in sub-Saharan Africa, small by global standards, have provided array global reinsurers.
Clover Biopharmaceuticals, a global clinical biotechnology company aimed at the discovery and progression of vaccines and transformative biological treatments, announced Array. .
Elliptic Labs announced that it has authorized its synthetic intelligence software to a primary device manufacturer. This non-exclusive Array license agreement.
Industry leaders and analysts express their views and responses to business resilience after the SINGAPORE – Media OutReach pandemic – September 25, 2020
LONDON, 25 September 2020 / PRNewswire / – AETOS Capital Group (AETOS) has won two more awards at the Global the Forex Market AwardsArray.
Regulatory developments: Lysogene (Paris: LYS) (FR0013233475 – LYS), a phase 3 gene treatment platform Diseases of the central nervous system formula company (CNS), Array . .
Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co. , Ltd. (Tokyo, Japan) announced that Japan’s Ministry of Health, LaborArray. .
Regulatory news: Ipsen (Euronext: IPN; ADR: IPSEY) announced the appointment of Philippe Lopes-Fernandes as Deputy Ceo, Director of BusinessArray.
SINGAPORE – Media OutReach – September 25, 2020 – Singapore’s cross-border invoice company TranSwap won the Platinum AwardArray award.
Mandatory cookies are surely for the proper functioning of the site. This category includes only cookies that provide the fundamental capacity and security features of the website. These cookies do not purchase any non-public information.